Highest-materiality recent filing
57% of evaluable patients (31/54) achieved responder status at one year, comparable to 63% at 12 weeks in Phase 2 Avail trial.
MBX 4291 Phase 1 shows 7% mean weight loss at 8 weeks; MBX 5765 nominated
Preliminary blinded data: mean weight loss 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, incl. 2 placebo).
MBX Biosciences Q1 net loss $23.5M; Phase 3 canvuparatide start on track for Q3 2026
Cash, equivalents and marketable securities of $440M; expected to fund operations into 2029.
MBX Biosciences reports FY2025 net loss of $87M; Phase 3 canvuparatide on track for Q3 2026
Net loss FY2025 $87.0M vs $61.9M in 2024; R&D expenses $79.2M, up from $57.4M.
MBX Biosciences successful End-of-Phase 2 FDA meeting; Phase 3 trial for canvuparatide in Q3 2026
Phase 3 double-blind placebo-controlled trial will enroll ~160 patients; 3:1 randomization, 4-week fixed 600 ug dose then 18-week titration, 4-week maintenance.
MBX Biosciences CFO Richard Bartram resigns; John Smither named interim CFO
CFO Richard Bartram resigns effective March 15, 2026; will serve as consultant post-resignation.
MBX Biosciences raises ~$87.1M in ATM offering; 2.25M shares sold at $38.76 VWAP
Closed sale of 2,250,986 shares at a volume-weighted average price of $38.76 for gross proceeds of approximately $87.1 million on February 4, 2026.
MBX Biosciences reports $373.7M cash, expands obesity pipeline with two new candidates in 2026
Preliminary unaudited cash, cash equivalents and marketable securities of $373.7M at Dec 31, 2025; runway into 2029.
MBX posts positive Phase 2 results for canvuparatide; Q3 net loss $21.6M; cash $391.7M
Q3 2025 net loss $21.6M vs $18.1M YoY; cash and equivalents $391.7M (includes $200M offering proceeds) funding into 2029.
MBX Biosciences raises $187.5M via public offering of 11.1M shares at $18.00
Offering of 11,108,055 shares at $18.00 per share; underwriters have 30-day option for up to 1,666,208 additional shares.
Primary composite endpoint met: 63% (30/48) of canvuparatide patients vs 31% (5/16) placebo at Week 12 (p=0.042).
MBX Biosciences Q2 net loss $19.4M; cash $224.9M; canvuparatide Phase 2 data on track for Q3 2025
Net loss $19.4M for Q2 2025 vs $15.9M in Q2 2024; R&D expenses increased to $17.7M.
MBX Biosciences submits IND for MBX 4291, once-monthly GLP-1/GIP obesity prodrug
IND submitted to FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug for obesity.
MBX Biosciences reports FY2024 net loss of $61.9M; pipeline milestones for 2025
Cash and marketable securities $262.1M as of Dec 31, 2024; expected to fund operations into mid-2027.
MBX Biosciences announces positive Phase 1 topline results for MBX 1416 for PBH; cash $262.1M
MBX 1416 generally well-tolerated; no dose-related serious adverse events; mild/moderate ISRs in 88% resolved ~7 days.
MBX Biosciences Q3 net loss $18.1M; cash $277M funds into mid-2027; IPO raised $251M
Net loss for Q3 2024 was $18.1M vs $10.2M in Q3 2023; R&D spend rose to $16.7M from $9.1M.
Also effective as of June 5, 2025 was the departure of Carl L. Gordon, Ph.D., CFA from the Company's board of directors.
Effective as of April 7, 2025, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.
Max materiality 0.85 · Median 0.65 · Most common event other_material